FOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent Tissues

Sponsor

xiaoliang Huang (Other)

Overall Status

Recruiting

CT.gov ID

NCT05698082

Collaborator

(none)

120

Enrollment

Location

Arm

Anticipated Duration (Months)

2.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Colorectal cancer tissue sections were obtained according to the inclusion criteria. The formalin was used to immersed all cancer specimens. And tissues were cut to 5 μm thickness and placed on glass slides before staining. Endogenous peroxidase activity was inhibited and blocked by de-paraffinizing, rehydrating, and using 5% bovine serum albumin at 37ºC for 30 min. The treated sections were incubated with anti-FOS (promab 30360) at 4ºC overnight and washed three times with PBS. After that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºC for 30 minutes. After washing three times again with PBS, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.

Condition or Disease	Intervention/Treatment	Phase
Colorectal Cancer Monkey Pox	Diagnostic Test: Immunohistochemical staining with anti-FOS	Phase 2/Phase 3

Study Design

Study Type:

Interventional

Anticipated Enrollment :

120 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Diagnostic

Official Title:

Monkeypox and Cancer: a Pan-cancer Based Multi-omics Analysis and Single Cell Sequencing Analysis-Experimental Studies

Actual Study Start Date :

Dec 1, 2020

Anticipated Primary Completion Date :

Jan 1, 2025

Anticipated Study Completion Date :

Jan 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Test group-stained by FOS antibody Sixty colorectal cancer tissue sections were included. The tissue was cut to 5 μm thick and placed on a glass slide for staining. Endogenous peroxidase activity was inhibited and blocked by deparaffin, rehydration, and treatment with 5% bovine serum albumin for 30 min at 37 ° C. The treated sections were incubated with anti-FOS (promab 30360) overnight at 4 ° C and washed three times with PBS. After that, it was required to incubate with secondary anti-peroxidation sunflower for 30 min at 37 ° C. After washing three times with PBS, the images were developed in diamine benzidine and micrographs were obtained under a light microscope.	Diagnostic Test: Immunohistochemical staining with anti-FOS The tissue sections were incubated with anti-FOS (promab 30360) at 4ºC overnight and washed three times with PBS. After that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºC for 30 minutes. After washing three times again with PBS, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.

Arm

Intervention/Treatment

Experimental: Test group-stained by FOS antibody

Sixty colorectal cancer tissue sections were included. The tissue was cut to 5 μm thick and placed on a glass slide for staining. Endogenous peroxidase activity was inhibited and blocked by deparaffin, rehydration, and treatment with 5% bovine serum albumin for 30 min at 37 ° C. The treated sections were incubated with anti-FOS (promab 30360) overnight at 4 ° C and washed three times with PBS. After that, it was required to incubate with secondary anti-peroxidation sunflower for 30 min at 37 ° C. After washing three times with PBS, the images were developed in diamine benzidine and micrographs were obtained under a light microscope.

Diagnostic Test: Immunohistochemical staining with anti-FOS

The tissue sections were incubated with anti-FOS (promab 30360) at 4ºC overnight and washed three times with PBS. After that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºC for 30 minutes. After washing three times again with PBS, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.

Outcome Measures

Primary Outcome Measures

Original survival [Participants were followed up for 3 years, including outpatient follow-up and telephone follow-up.]
Time from the start of the study to death from any cause. For subjects who were lost to follow-up before death, the time of last follow-up was calculated as the time of death.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Inclusion Criteria:

(a) patients with histologically confirmed CRC (b) patients who underwent resection of the primary tumor (c) patients at first visit who had not received treatment before blood testing.

Exclusion Criteria:

(a) familial adenomatous polyposis or hereditary colon cancer (b) no signs of clinical infection, such as fever, on the day of blood collection; And (c) patients with multiple primary tumors during hospitalization.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Guangxi Medical University Cancer Hospital	Nanning	Guangxi	China

Sponsors and Collaborators

xiaoliang Huang

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

xiaoliang Huang, clinical Professor, Cancer Hospital of Guangxi Medical University

ClinicalTrials.gov Identifier:

NCT05698082

Other Study ID Numbers:

KY-2020-305

First Posted:

Jan 26, 2023

Last Update Posted:

Jan 26, 2023

Last Verified:

Jan 1, 2023

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Product Manufactured in and Exported from the U.S.:

Keywords provided by xiaoliang Huang, clinical Professor, Cancer Hospital of Guangxi Medical University

Differential expression of gene

Immunohistochemical staining

Tumor microenvironment

Additional relevant MeSH terms:

Monkeypox

Colorectal Neoplasms

Study Results

No Results Posted as of Jan 26, 2023